AB0757 ANALYSIS OF THE PROGNOSTIC VALUE OF THE 12-ITEM PSORIATIC ARTHRITIS IMPACT OF DISEASE (PSAID-12) QUESTIONNAIRE FOR EVALUATION OF PSORIATIC ARTHRITIS ACTIVITY(PSA) BY DISEASE ACTIVITY INDEX FOR PSORIATIC ARTHRITIS (DAPSA) IN ROUTINE CARE: DATA OF THE RUSSIAN PSORIATIC ARTHRITIS REGISTRY(RU-PSART)
Authors: Anastasia Koltakova, Elena Loginova, Elena Gubar, Yulia Korsakova, Tatiana Korotaeva, Maria Sedunova, Igor Pristavsky, Irina Umnova, Irina Bondareva, Snezana Kudishina, Evgeny Nasonov
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> The PsAID-12 is an instrument for assessment the impact of PsA on patients' lives by examine both physical and psychological components of health. DAPSA is a valid and discriminative tool for evaluation of the PsA activity. There is limited data about the PsAID-12 correlations with PsA activity by DAPSA in clinical care [1]. The Russian Psoriatic arthritis Registry (RU-PsART) collected data from 25 rheumatology clinics in the Russian Federation regions. Objectives: to investigate the predictive value of the PsAID-12 for evaluate PsA activity by DAPSA in real-world settings. <h3>Methods:</h3> 138 (male/female–79/59) patients (pts), median age 40 (Min-Max/23-71), with PsA, according to CASPAR criteria, were included in the RU-PsART after signing consent participation forms. Every 6 months (259 visits total) all pts underwent evaluation of PsA activity: the Tender Joint count (TJC68), Swollen Joint Count (SJC66), Leeds Enthesitis index (LEI), physician's global disease activity (PhGA) VAS, CRP (mg/l), ESR (mm/h), by PROs - patient pain global assessment VAS, Patient global disease activity (PGA) VAS and the PsAID-12. PsA activity was calculated by DAPSA. All pts were divided into 2 groups based on disease activity state by DAPSA: the first one with results ≤14 that interpreted as Remission and Low Disease activity (REM and LDA) and second one with results &gt;14 that interpreted as Moderate and High Disease activity (MoDA and HDA). Pearson correlation coefficient and ROC-curve analysis were performed. All p&lt;0.05 were considered to indicate statistical significance. <h3>Results:</h3> The Significant positive correlations between the PsAID-12 and all parameters of PsA activity, PROs were found (table 1). The Significant positive correlations for DAPSA (r=0,71) were found. The high prognostic value of the PsAID-12 for PsA activity by DAPSA showed by ROC-curve analysis (AUC=0,89, CI 95% (0,85-0,93)). The threshold for MoDA and HDA (DAPSA &gt;14) by PsAID was 1. <h3>Conclusion:</h3> The PsAID-12 has a significant prognostic value for PsA activity by DAPSA. The questionnaire doesn't include any physician's or laboratory's data, so it could be useful as a simple instrument for pts' self-control and prognosis disease activity in daily clinical practice. <h3>References</h3> [1] Di Carlo M, Becciolini a, Lato V. et al. The 12-item Psoriatic arthritis Impact of Disease Questionnaire: Construct Validity, Reliability, and interpretability in a Clinical Setting. J Rheumatol. 2017;44(3):279-285. doi: 10.3899/jrheum.160924 <h3>Disclosure of interests:</h3> Anastasia Koltakova: None declared, Elena Loginova Speakers bureau: Novartis, Celgene Corporation, Biocad, Janssen, abbVie inc, ELENA GUBAR: None declared, Yulia Korsakova Speakers bureau: Celgene Corporation, Janssen, Tatiana Korotaeva Speakers bureau: Novartis, Celgene Corporation, abbVie inc, Biocad, Janssen, Pfizer, UCB, Lilly, Maria Sedunova: None declared, Igor Pristavsky: None declared, Irina Umnova: None declared, Irina Bondareva: None declared, Snezana Kudishina: None declared, Evgeny Nasonov: None declared